ALLO - CIK 0001737287
Allogene Therapeutics, Inc. trades as ALLO. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$190.89M. This page tracks Allogene Therapeutics, Inc. through 558 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -159.6% to -1170863.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Proxy materials | DEFA14A | 2026-05-21 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| Annual report to shareholders | ARS | 2026-04-30 |
The largest companies sharing Allogene Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Allogene Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year Allogene Therapeutics, Inc. reported a net loss of $190.89M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.